VRTXHealthcare · BiotechnologyThe 29 Wall Street analysts covering Vertex Pharmaceuticals, Inc. hold a median 12-month price target of $570 — +7.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 10 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Vertex Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Accruals (28): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
The bullish and bearish analyst opinions on VRTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +7.6% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Aug 2026 | Barclays | Maintains | Overweight | $615 → $617 |
| 5 Aug 2026 | Truist Securities | Maintains | Buy | $560 → $565 |
| 4 Aug 2026 | Canaccord Genuity | Maintains | Hold | $436 → $442 |
| 4 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $590 → $595 |
| 4 Aug 2026 | TD Cowen | Maintains | Buy | $525 → $550 |
| 13 July 2026 | Truist Securities | Maintains | Buy | $542 → $560 |
| 13 July 2026 | Truist Securities | Maintains | Buy | — |
| 13 July 2026 | UBS | Maintains | Buy | $545 → $585 |
| 13 July 2026 | UBS | Maintains | Buy | — |
| 7 July 2026 | Baird | Maintains | Underperform | $330 → $350 |
| 7 July 2026 | Baird | Maintains | Underperform | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $543 → $570 |
| 6 May 2026 | Barclays | Maintains | Overweight | — |
| 5 May 2026 | Bernstein | Maintains | Outperform | — |
| 5 May 2026 | Canaccord Genuity | Maintains | Hold | — |
| 5 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 5 May 2026 | RBC Capital | Maintains | Outperform | — |
| 30 Apr 2026 | Canaccord Genuity | Maintains | Hold | — |
| 10 Apr 2026 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRTX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 27% of US stocks
Cheaper than 14% of US stocks
Cheaper than 16% of US stocks
Cheaper than 13% of US stocks
Higher than 59% of US stocks
Higher than 44% of US stocks
Higher than 94% of US stocks
Higher than 91% of US stocks
Higher than 92% of US stocks
Higher than 84% of US stocks
Higher than 95% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
The rank is the raw material. Whether the rules would actually own Vertex Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research named Vertex Pharmaceuticals among four biotech stocks facing major second-half pipeline catalysts, including FDA decisions and late-stage readouts in 2026.
Why it matters — VRTX watchers would care because the article highlights upcoming pipeline events that could serve as key catalysts for the company's stock later this year.
Vertex Pharmaceuticals' stock rose on Monday following a disappointing result for competitor Sionna Therapeutics' highly anticipated cystic fibrosis treatment. The rival's shares fell sharply as a result.
Why it matters — A setback for a key competitor in cystic fibrosis could reduce competitive pressure on Vertex's own treatments in that market.
Vertex Pharmaceuticals could face competition in its most important market, cystic fibrosis, according to the report. The company is preparing for this by diversifying its lineup and pipeline.
Why it matters — A VRTX watcher would care because potential competition in its core cystic fibrosis market and the company's diversification efforts directly affect its main business outlook.
A Barron's article notes that healthcare stocks have been overlooked by the market this year, and names Eli Lilly, McKesson, and nine other companies as buys, suggesting many in the sector look ready to gain.
Why it matters — A renewed focus on undervalued healthcare names could draw more investor attention to the sector, potentially benefiting Vertex as part of it.
Vertex Pharmaceuticals stock ticked higher on Tuesday. The company reported double-digit sales growth, though net profit growth was more modest.
Why it matters — A VRTX watcher would care because strong sales growth signals healthy business momentum, while modest profit growth and other developments worth monitoring could affect the company's outlook.
The 29 Wall Street analysts covering Vertex Pharmaceuticals, Inc. have a median 12-month price target of $570, with estimates ranging from $350 to $653. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 29 analysts covering Vertex Pharmaceuticals, Inc., 23 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Vertex Pharmaceuticals, Inc. 69 out of 100 across roughly 4,600 US stocks as at 10 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Aug 2026, Vertex Pharmaceuticals, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 29 analysts implies +7.6% from the last close, and Ticker Nerd's factor model ranks Vertex Pharmaceuticals, Inc. 69 out of 100 as at 10 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vertex Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $350 to $653 over the next 12 months.
Vertex Pharmaceuticals, Inc. returned +41.4% over the 12 months to 11 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing transformative medicines for serious diseases. The company is best known for its leadership in cystic fibrosis, where it markets a portfolio of CFTR modulator therapies such as Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, Kalydeco and Alyftrek that address underlying genetic defects in eligible patients across multiple age groups.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year". Zacks Investment Research named Vertex Pharmaceuticals among four biotech stocks facing major second-half pipeline catalysts, including FDA decisions and late-stage readouts in 2026.
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing transformative medicines for serious diseases. The company is best known for its leadership in cystic fibrosis, where it markets a portfolio of CFTR modulator therapies such as Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, Kalydeco and Alyftrek that address underlying genetic defects in eligible patients across multiple age groups. Beyond cystic fibrosis, Vertex today provides and develops treatments for sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain, as well as investigational therapies for APOL1-mediated kidney disease and other severe conditions. Headquartered in Boston, Massachusetts and founded in 1989, Vertex operates across the United States, Europe, and internationally, serving specialized markets through a combination of proprietary drug development, advanced research collaborations, and global commercialization capabilities. Its portfolio positions the company as a key player in specialty care within the broader healthcare and biotechnology sectors.
CEO Dr. Reshma Kewalramani FASN, M.D. · 6,400 employees · United States · https://www.vrtx.com